Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency × olaparib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 3 Ovarian Neoplasms 3 Stomach Neoplasms 1 Solid Tumor 1 Prostatic Neoplasms 1 Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07113964 2025-08-11

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting

Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon ⚡